Lexaurin (Bromazepam)

Bromazepam binds to the benzodiazepine site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the effect of the inhibitory neurotransmitter GABA, increasing chloride ion influx, which dampens neuronal excitability and produces a calming, anxiolytic effect.

The appropriate dose of Lexaurin is determined by the prescribing clinician based on the patient’s age, clinical condition, and response to therapy. Dosage may be adjusted for renal or hepatic impairment, and treatment duration is generally limited to the shortest period necessary to control symptoms.

Bromazepam is generally not recommended during pregnancy or lactation because it can cross the placenta and appear in breast milk, potentially affecting the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatments with their healthcare provider.

To request Lexaurin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lexaurin (bromazepam) shares the core anxiolytic mechanism of other benzodiazepines such as diazepam or lorazepam but differs in potency, half‑life and metabolic profile. Bromazepam is considered intermediate‑acting, offering effective anxiety control with a lower risk of accumulation compared with longer‑acting agents.

Lexaurin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and direct light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Lexaurin is supplied as an oral tablet and should be swallowed whole with a glass of water. It is taken by mouth as directed by the prescriber, typically with or without food, and should not be crushed or chewed unless specifically advised.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions, and the potential for dependence, tolerance and withdrawal symptoms after prolonged use. Patients should be monitored closely for these events.

Lexaurin is contraindicated in patients with acute narrow‑angle glaucoma, severe respiratory insufficiency, severe hepatic impairment, or a known hypersensitivity to bromazepam or any benzodiazepine component. It should also be avoided in individuals with a history of substance misuse unless closely supervised.